| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Melissa C Brouwers | |
| Brian H Dingle | |||
| Cancer Care Ontario's Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group | |||
| R Bryan Rumble | |||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| gallbladder cancer | Q977787 | ||
| P304 | page(s) | 711-716 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Canadian Journal of Gastroenterology | Q15749648 |
| P1476 | title | The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review | |
| P478 | volume | 19 |
| Q50795703 | Adjuvant chemotherapy in resectable cholangiocarcinoma patients. |
| Q37698980 | Cholangiocarcinoma: has there been any progress? |
| Q35429914 | Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer |
| Q52727952 | Effect of CLIC1 gene silencing on proliferation, migration, invasion and apoptosis of human gallbladder cancer cells. |
| Q39147921 | Effect of external beam radiotherapy on patency of uncovered metallic stents in patients with inoperable bile duct cancer |
| Q37521588 | Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells |
| Q37167436 | Gallbladder cancer--a comprehensive review. |
| Q33385766 | Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study |
| Q40054530 | Gemcitabine and capecitabine for advanced biliary cancer |
| Q35017050 | Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer |
| Q38163597 | Hepatocellular carcinoma and cholangiocarcinoma: an update |
| Q35197256 | Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes. |
| Q46035707 | Impact of rhenium-188, gemcitabine, and 5-fluorouracil on cholangiocellular carcinoma cells: an in vitro study. |
| Q40256333 | Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma |
| Q34099099 | Multi-disciplinary treatment for cholangiocellular carcinoma |
| Q34391135 | New insights on cholangiocarcinoma. |
| Q34007429 | Precancerous lesions of the gallbladder |
| Q38119166 | Prognosis analysis of sarcomatous intrahepatic cholangiocarcinoma from a review of the literature |
| Q37206908 | Recent advances of cocktail chemotherapy by combination drug delivery systems. |
| Q35607681 | Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. |
| Q36455955 | Review article: the modern diagnosis and therapy of cholangiocarcinoma |
| Q47110509 | Successful local treatment for repeated hepatic recurrences of cholangiolocellular carcinoma: a report on a long-term survivor. |
| Q39703338 | The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid |
| Q61447222 | The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer: A STROBE-compliant retrospective cohort study |
| Q35244211 | The prognostic importance of lymphovascular invasion in cholangiocarcinoma above the cystic duct: a new selection criterion for adjuvant therapy? |
| Q45271181 | Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. |
| Q38294428 | Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target |
Search more.